News archive
Showing 745 results
December 2012
-
Media Release
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)- In the Phase III trial, most patients… -
Media Release
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
November 2012
-
Media Release
Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
RELAX-AHF study met one of its two primary endpoints in reducing dyspnea or shortness of breath, and was therefore positive under pre-specified criteriaNewly presented data show that at six months,… -
Media Release
Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
October 2012
-
Media Release
Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
- Leeza and family share highs, lows and insights about caring for her mother with Alzheimer's disease in new video series- Ten national contest winners recognized for words of wisdom about finding… -
Media Release
Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
September 2012
-
Media Release
Novartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer
La iniciativa busca ayudar a cerrar la brecha del diagnóstico de los hispanos a través de recursos e información en español sobre la enfermedad de Alzheimer La compañía trabajará junto a Univision… -
Media Release
Novartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community
The initiative aims to help close diagnosis gap for Hispanic Americans by providing in-language information and resources focused on Alzheimer’s diseaseThe company will work with Univision to help… -
Media Release
Novartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer
-
Media Release
Novartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community
-
Media Release
FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
-Tobramycin inhalation powder (TIP) recommended for management of cystic fibrosis (CF) patients six years and older with P. aeruginosa bacteria in their lungs-P. aeruginosa (Pa) is the leading cause… -
Media Release
FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis